← Back to Search

Beta-3 Adrenergic Agonist

Mirabegron for Temperature Regulation

Phase < 1
Waitlist Available
Led By Christopher Bell, Ph.D.
Research Sponsored by Christopher Bell
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18-40 years
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up immediately after each infusion.
Awards & highlights

Study Summary

This trial found that taking mirabegron can increase fat-burning and improve glucose regulation, possibly changing muscle structure.

Who is the study for?
This trial is for healthy adults aged 18-40 who exercise regularly (over 150 minutes of moderate intensity weekly) for the past two years. It's not suitable for pregnant or breastfeeding individuals, those with heart, lung, metabolic diseases like diabetes, liver/kidney problems, or on certain medications that don't mix well with Mirabegron.Check my eligibility
What is being tested?
The study tests if Myrbetriq (Mirabegron), a drug normally used to treat overactive bladder, can increase body heat produced by brown fat compared to a placebo. The goal is also to see if it has long-term benefits on glucose regulation and muscle changes.See study design
What are the potential side effects?
Possible side effects of Mirabegron include increased blood pressure, urinary tract infections, headaches, dizziness, nausea and could potentially interact unfavorably with other drugs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 40 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~immediately after each infusion.
This trial's timeline: 3 weeks for screening, Varies for treatment, and immediately after each infusion. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in core temperature measured via oral thermometer during each stage.
Change in metabolic rate compared to baseline during each stage as measured by indirect calorimetry
Change in temperature among the top 10% of hottest pixels as identified via thermal camera and FLIR research software in the supraclavicular region during each isoproterenol infusion.

Side effects data

From 2019 Phase 4 trial • 28 Patients • NCT02086188
7%
fatigue
7%
asthma
7%
urinary tract infection
7%
headache
7%
gastritis
7%
diarrhea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Mirabegron
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Mirabegron + IsoproterenolExperimental Treatment1 Intervention
100mg oral + Isoproterenol IV Infusion; 3 doses, 6, 12, 24ng/ kg Fat Free Mass
Group II: Placebo + IsoproterenolPlacebo Group1 Intervention
Empty Capsule + Isoproterenol IV Infusion; 3 doses, 6, 12, 24ng/ kg Fat Free Mass

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Mirabegron, a beta3-adrenoceptor agonist, enhances temperature regulation by activating and upregulating brown adipose tissue (BAT). This activation increases thermogenesis, the process by which brown fat generates heat by burning calories. For patients with temperature regulation issues, this mechanism is crucial as it helps maintain body temperature and improve metabolic functions, potentially offering a therapeutic approach to conditions like obesity and metabolic syndrome where temperature regulation is impaired.
Horizons in the Pharmacotherapy of Obesity.

Find a Location

Who is running the clinical trial?

Indiana UniversityOTHER
993 Previous Clinical Trials
1,095,270 Total Patients Enrolled
Christopher BellLead Sponsor
8 Previous Clinical Trials
211 Total Patients Enrolled
Christopher Bell, Ph.D.Principal InvestigatorColorado State University
1 Previous Clinical Trials
62 Total Patients Enrolled
~9 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top